Brain‐Targeted Near‐Infrared Chiral TeSe Nanodrug Against Orthotopic Drug‐Resistant Glioma
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.202516990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Yisheng Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Special Functional Materials of Ministry of Education, Henan University, Kaifeng, Henan, 475004, China. Hauptthemen laut MEDLINE: Glioma, Antineoplastic Agents, Drug Resistance, Neoplasm, Selenium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research Projects of Higher Education Institutions in Henan Province, Natural Science Foundation of Henan.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) remains a formidable therapeutic challenge due to its high invasiveness, the highly restrictive blood–brain barrier (BBB), and frequent drug resistance, necessitating new therapeutic strategies. Here, we developed tellurium‐selenium nanoparticles (TeSe NPs) with exceptional near‐infrared (NIR) chiroptical properties and potent antitumor activity against drug‐resistant glioma for the first time. Notably, the right‐handed nanoparticles ( D ‐TeSe NPs) exhibited higher cellular uptake than left‐handed L ‐TeSe NPs through chirality‐selective recognition by drug‐resistant glioma cells. The Te and Se active centers in D ‐TeSe NPs selectively triggered severe oxidative stress in glioma cells, leading to redox imbalance, reactive oxygen species (ROS)‐mediated mitochondrial dysfunction, and ultimately causing 44.2% glioma cell death (versus 37.1% for L ‐TeSe NPs). When combined with 808 nm right‐handed circularly polarized light, D ‐TeSe NPs showed enhanced ROS generation, elevating therapeutic efficacy to 62.5% while maintaining negligible toxicity to normal cells. Furthermore, apolipoprotein E‐functionalized D ‐TeSe NPs demonstrated improved BBB penetration and tumor‐targeting capability, significantly extending the survival of mice with orthotopic drug‐resistant glioma to 52 days (versus 21 days for PBS control). This study pioneers a NIR and brain‐targeted chiral nanoplatform for precision therapy of orthotopic glioma, offering a chirality‐driven paradigm against drug‐resistant malignancies and other brain diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Special Functional Materials of Ministry of Education, Henan University, Kaifeng, Henan, 475004, China.
- Department of Clinical Laboratory of Huaihe Hospital, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China.
ORCID-Profile: Feng Bai
Förderung
- National Natural Science Foundation of China
- Key Research Projects of Higher Education Institutions in Henan Province
- Natural Science Foundation of Henan
- Joint Training Funds for Science & Technology R&D of Henan Province
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Liu, Y., Li, X., Zhu, Q., Zhong, Y., Lin, X., Zhou, C., Qi, C., Guo, J., Ma, Q., Wu, H., Wang, G., Bai, F., & Wang, J. (2026). Brain‐Targeted Near‐Infrared Chiral TeSe Nanodrug Against Orthotopic Drug‐Resistant Glioma. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202516990
Vancouver
Liu Y, Li X, Zhu Q, Zhong Y, Lin X, Zhou C, et al. Brain‐Targeted Near‐Infrared Chiral TeSe Nanodrug Against Orthotopic Drug‐Resistant Glioma. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.202516990
BibTeX
@article{Liu2026,
author = {Liu, Yisheng and Li, Xi and Zhu, Qingxiang and Zhong, Yong and Lin, Xuhong and Zhou, Chaoqun and Qi, Cai and Guo, Jincheng and Ma, Qinqin and Wu, Haigang and Wang, Gaoyang and Bai, Feng and Wang, Jiefei},
title = {Brain‐Targeted Near‐Infrared Chiral TeSe Nanodrug Against Orthotopic Drug‐Resistant Glioma},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.202516990}
}
EUVIMED